Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Inflammatory Bowel Disease (IBD) & Drugs/Treatments

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Neutralizing cytokines is a recognized treatment for IBD.
Zahirović & Berlec 2022 Microb Cell Fact 21: 143

Agents that block cytokines, like TNF, suppress the immune system.

These agents are clinically effective for patients with IBD.

Zhang et al. 2022h Cell Communication and Signaling 20: 64

The Inflammatory Bowel Disease (IBD) treatment option is beyond biologic agents widened with recent approvals of anti-integrins (e.g., vedolizumab and natalizumab) and [sphingosine-1-phosphate (S1P) receptor modulators](brain://03r4OMOBBUi-g…

References (Sources)

Breaking the therapeutic ceiling in drug development in ulcerative colitis
Alsoud et al. 2021 Lancet Gastroenterol Hepatol 6(7): 589-595
Review
Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD
Pippis et al. 2021 Inflamm Bowel Dis 27(10): 1674
Review
Intestinal antiinﬂammatory eﬀect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor- γ
Rousseaux et al. 2005 Journal of Experimental Medicine 201(8): 1205–1215
Regulatory role of short-chain fatty acids in inflammatory bowel disease
Zhang et al. 2022h Cell Communication and Signaling 20: 64
Review
Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: Their mechanisms of action and role in the treatment of IBD
Van Dieren et al. 2006 Inﬂamm. Bowel Dis. 12: 311–327
Sphingosine-1 phosphate receptor modulators: the next wave of oral therapies in inﬂammatory bowel disease
Choden et al. 2022 Gastroenterol Hepatol (N. Y.) 18: 265-271
Review
Targeting Immune Cell Metabolism in the Treatment of Inflammatory Bowel Disease
Bittencourt et al. 2021 Inflamm Bowel Dis 27(10): 1684
Review

AI Chat

6/24/2026

Chat with our artificial intelligence: